Medicare Part D Market Analysis
Cross-industry research covering Medicare Part D across 2 market reportsspanning Pharmaceuticals & Medical Devices — Ophthalmic Surgery, Pharmaceuticals / Medical Devices — Regional Anesthesia.
Reports Covering Medicare Part D
Oculoplastic Surgery Market to Reach USD 8.4 Billion by 2033 at 7.2% CAGR
Will grow significantly if subcutaneous or oral TED therapies receive approval and are classified as self-administered drugs under the pharmacy benefit; IRA-mandated out-of-pocket cap of USD 2,000 for Part D beneficiaries from 2025 onward improves patient affordability but may increase manufacturer rebate burden.
10%
Market Share
9.1%
Segment CAGR
Nerve Blocks Market to Reach USD 9.4 Billion by 2033 at 6.4% CAGR
Part D coverage of outpatient-dispensed nerve block adjuvants (oral formulations, take-home analgesics) is relevant primarily for transition analgesia rather than block agents themselves, which are clinic-administered. The IRA's Medicare Drug Price Negotiation Program, which began with the first ten drugs selected in 2023, is not directly applicable to the off-patent generic agents dominating this space, but aggregate Part D formulary structure shapes post-procedure analgesic prescribing patterns that influence block utilization intensity.
8%
Market Share
5.0%
Segment CAGR